Talk:Lenvatinib
Jump to navigation
Jump to search
| This is the talk page for discussing improvements to the Lenvatinib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: |
||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lenvatinib.
|
Melanoma Study
There is a study with E7080 for Melanoma now as well: http://www.clinicaltrials.gov/ct2/show/study/NCT01136967 —Preceding unsigned comment added by 212.23.103.38 (talk) 12:53, 21 February 2011 (UTC)
Why is it a multiple kinase inhibitor
What is it about the structure or shape of the molecule that makes it a multiple kinase inhibitor ? - Rod57 (talk) 16:59, 14 December 2016 (UTC)
- Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization says (with diagram) "Co-crystal structure analysis demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-“in” conformation. These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors." - (quinoline is the 2 adjacent rings on the LHS, cyclopropane is the triangle on the RHS). Suggests that to some extent it acts as an ATP mimetic. - Rod57 (talk) 18:31, 14 December 2016 (UTC)